The Food and Drug Administration released new draft guidance for labeling medications that carry the risk of abuse or dependence, including but not limited to opioids, and simplifying labels with complicated usage instructions. Changes for potentially habit-forming  include defining terminology, such as abuse, misuse, addiction, physical dependence and tolerance, to avoid misinterpretation on labels. According to the guidance, opioid-specific labeling should include information about how health care professionals can safely decrease the dosage in physically dependent patients, with a goal of finding the balance in pain management and reduced use. For medications with detailed instructions for use, the FDA patient-friendly visual guides that are consistent in content and format.

Related News Articles

Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…
Headline
In this conversation, Vinnidhy Dave, D.O., hospice specialist and director of palliative medicine at Englewood Health Physician Network, and Lauren Savage,…
Headline
In this conversation, Matthew Hoag, director of integrated behavioral health at Denver Health, shares how the organization is innovating through integration to…
Headline
Oct. 28 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired tablets, capsules, patches and…
Headline
Federal agencies last month stopped over 500 unapproved pharmaceutical products and medical devices, including opioid and other controlled substances, from…
Headline
As the House Energy and Commerce Committee works to reauthorize key programs within the Substance Use-Disorder Prevention that Promotes Opioid Recovery and…